{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:23:54Z","timestamp":1774358634175,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"S8","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI-SPORE-2P50CA101942-11A1"],"award-info":[{"award-number":["NCI-SPORE-2P50CA101942-11A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA216772-01A1"],"award-info":[{"award-number":["R21 CA216772-01A1"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We previously developed TANTIGEN, a comprehensive online database cataloging more than 1000\u00a0T cell epitopes and HLA ligands from 292 tumor antigens. In TANTIGEN 2.0, we significantly expanded coverage in both immune response targets (T cell epitopes and HLA ligands) and tumor antigens. It catalogs 4,296 antigen variants from 403 unique tumor antigens and more than 1500\u00a0T cell epitopes and HLA ligands. We also included neoantigens, a class of tumor antigens generated through mutations resulting in new amino acid sequences in tumor antigens. TANTIGEN 2.0 contains validated TCR sequences specific for cognate T cell epitopes and tumor antigen gene\/mRNA\/protein expression information in major human cancers extracted by Human Pathology Atlas. TANTIGEN 2.0 is a rich data resource for tumor antigens and their associated epitopes and neoepitopes. It hosts a set of tailored data analytics tools tightly integrated with the data to form meaningful analysis workflows. It is freely available at<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/projects.met-hilab.org\/tadb\">http:\/\/projects.met-hilab.org\/tadb<\/jats:ext-link>.<\/jats:p>","DOI":"10.1186\/s12859-021-03962-7","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T23:21:08Z","timestamp":1618356068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-490X","authenticated-orcid":false,"given":"Guanglan","family":"Zhang","sequence":"first","affiliation":[]},{"given":"Lou","family":"Chitkushev","sequence":"additional","affiliation":[]},{"given":"Lars R\u00f8nn","family":"Olsen","sequence":"additional","affiliation":[]},{"given":"Derin B.","family":"Keskin","sequence":"additional","affiliation":[]},{"given":"Vladimir","family":"Brusic","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"3962_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-030-23765-3_6","volume":"214","author":"A Paschen","year":"2020","unstructured":"Paschen A, Schadendorf D. The era of checkpoint inhibition: lessons learned from melanoma. Recent Results Cancer Res. 2020;214:169\u201387.","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"3962_CR2","first-page":"1","volume":"14","author":"H Dave","year":"2019","unstructured":"Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D. Driving the CAR to the bone marrow transplant program. Curr Hematol Malignancy Rep. 2019;14(6):1\u20139.","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"127","key":"3962_CR3","first-page":"8","volume":"4","author":"SA Rosenberg","year":"2021","unstructured":"Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med. 2021;4(127):8.","journal-title":"Sci Transl Med"},{"issue":"6","key":"3962_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724\u201330.","journal-title":"Nat Med"},{"issue":"47","key":"3962_CR5","doi-asserted-by":"publisher","first-page":"ra 64","DOI":"10.1126\/scitranslmed.3001442","volume":"2","author":"HS Robins","year":"2010","unstructured":"Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, et al. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med. 2010;2(47):ra 64.","journal-title":"Sci Transl Med"},{"issue":"1675","key":"3962_CR6","doi-asserted-by":"publisher","first-page":"20140291","DOI":"10.1098\/rstb.2014.0291","volume":"370","author":"DJ Laydon","year":"2015","unstructured":"Laydon DJ, Bangham CR, Asquith B. Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach. Philos Trans R Soc B Biol Sci. 2015;370(1675):20140291.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"3962_CR7","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3389\/fimmu.2018.02729","volume":"9","author":"JH Cui","year":"2018","unstructured":"Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP, Su XK, et al. TCR repertoire as a novel indicator for immune monitoring and prognosis assessment of patients with cervical cancer. Front Immunol. 2018;9:2729.","journal-title":"Front Immunol"},{"key":"3962_CR8","doi-asserted-by":"crossref","unstructured":"Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, et al. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI insight 2018;3(13).","DOI":"10.1172\/jci.insight.122092"},{"issue":"7662","key":"3962_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321.","journal-title":"Nature"},{"issue":"7738","key":"3962_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234\u20139.","journal-title":"Nature"},{"issue":"9","key":"3962_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909\u201315.","journal-title":"Nat Med"},{"issue":"1","key":"3962_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","volume":"1","author":"N Hacohen","year":"2013","unstructured":"Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013;1(1):11\u20135.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3962_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","volume":"12","author":"T Boon","year":"1994","unstructured":"Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12(1):337\u201365.","journal-title":"Annu Rev Immunol"},{"issue":"6C","key":"3962_CR14","first-page":"5535","volume":"19","author":"JH Coggin Jr","year":"1999","unstructured":"Coggin JH Jr, Barsoum AL, Rohrer JW. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res. 1999;19(6C):5535.","journal-title":"Anticancer Res"},{"issue":"3","key":"3962_CR15","first-page":"869","volume":"61","author":"MH Andersen","year":"2001","unstructured":"Andersen MH, Pedersen L\u00d8, Becker JC, thor Straten P. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Research. 2001;61(3):869\u201372.","journal-title":"Cancer Research"},{"issue":"7662","key":"3962_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"7738","key":"3962_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovi\u0107 S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240\u20135.","journal-title":"Nature"},{"issue":"26","key":"3962_CR18","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"26","key":"3962_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"3962_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin JG, Keskin DB, Sarkizova S, Hartigan CR, Zhang W, Sidney J, et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity. 2017;46(2):315\u201326.","journal-title":"Immunity"},{"issue":"2","key":"3962_CR21","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkn202","volume":"36","author":"C Lundegaard","year":"2008","unstructured":"Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8\u201311. Nucl Acids Res. 2008;36(2):W509-12.","journal-title":"Nucl Acids Res"},{"issue":"6","key":"3962_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00262-017-1978-y","volume":"66","author":"LR Olsen","year":"2017","unstructured":"Olsen LR, Tongchusak S, Lin H, Reinherz EL, Brusic V, Zhang GL. TANTIGEN: a comprehensive database of tumor T cell antigens. Cancer Immunol Immunother. 2017;66(6):731\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"3962_CR23","doi-asserted-by":"crossref","unstructured":"Zhang G, Chitkushev L, Keskin DB, Brusic V. TANTIGEN 2.0: an online database and analysis platform for tumor T cell antigens. In 2019 IEEE international conference on bioinformatics and biomedicine (BIBM) 2019;2228\u20132231.","DOI":"10.1109\/BIBM47256.2019.8983392"},{"key":"3962_CR24","unstructured":"Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immunity Archive 2013;13(3)."},{"issue":"10","key":"3962_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113.","journal-title":"Nat Genet"},{"key":"3962_CR26","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347:6220.","journal-title":"Science"},{"key":"3962_CR27","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1126\/science.aan2507","volume":"357","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:6352.","journal-title":"Science"},{"issue":"18","key":"3962_CR28","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1093\/bioinformatics\/btx286","volume":"33","author":"N Tickotsky","year":"2017","unstructured":"Tickotsky N, Sagiv T, Prilusky J, Shifrut E, Friedman N. McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences. Bioinformatics. 2017;33(18):2924\u20139.","journal-title":"Bioinformatics"},{"issue":"7","key":"3962_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1101\/pdb.top17","volume":"2007","author":"DW Mount","year":"2007","unstructured":"Mount DW. Using the basic local alignment search tool (BLAST). Cold Spring Harbor Protocols. 2007;2007(7):17.","journal-title":"Cold Spring Harbor Protocols"},{"issue":"4","key":"3962_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/bib\/bbn013","volume":"9","author":"K Katoh","year":"2008","unstructured":"Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform. 2008;9(4):286\u201398.","journal-title":"Brief Bioinform"},{"key":"3962_CR31","doi-asserted-by":"crossref","unstructured":"Zhang GL, Sun J, Chitkushev L, Brusic V. Big data analytics in immunology: a knowledge-based approach. BioMed Res Int 2014;2014.","DOI":"10.1155\/2014\/437987"},{"key":"3962_CR32","doi-asserted-by":"crossref","unstructured":"Zhang GL, Keskin D, Chitkushev L, Reinherz EL, Brusic V. EBVdb: a data repository and analysis platform for knowledge discovery in Epstein-Barr virus with applications in T cell immunotherapy. ICSI3 2015, July 17\u201318, Taomina, Italy.","DOI":"10.1109\/AISW.2015.7469232"},{"key":"3962_CR33","doi-asserted-by":"crossref","unstructured":"Zhang GL, Riemer AB, Keskin DB, Chitkushev L, Reinherz EL, Brusic V. HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology. Database. 2014;2014.","DOI":"10.1145\/2506583.2512360"},{"key":"3962_CR34","doi-asserted-by":"crossref","unstructured":"Zhang GL, Keskin DB, DeCaprio JA, Wu CJ, Chitkushev L, Brusic V. MCVdb: A database for knowledge discovery in Merkel cell polyomavirus with applications in T cell immunology and vaccinology. In 2017 IEEE international conference on bioinformatics and biomedicine (BIBM) 2017;1483\u20131488.","DOI":"10.1109\/BIBM.2017.8217881"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-03962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-021-03962-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-03962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T06:35:41Z","timestamp":1671863741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-021-03962-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":34,"journal-issue":{"issue":"S8","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3962"],"URL":"https:\/\/doi.org\/10.1186\/s12859-021-03962-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethics approval was required for the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DBK has previously advised and received consulting fees from Neon Therapeutics. DBK and GLZ own equity in Aduro Biotech, Agenus Inc., Armata pharmaceuticals, Breakbio Corp., Biomarin Pharmaceutical Inc., Bristol Myers Squibb Com., Celldex Therapeutics Inc., Editas Medicine Inc., Exelixis Inc., Gilead Sciences Inc., IMV Inc., Lexicon Pharmaceuticals Inc., Moderna Inc., Regeneron Pharmaceuticals, and Stemline Therapeutics Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}